Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer

• 資料種別: データセット
• タイトル: Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
• 著者標目: Mila Petrova; Ivan Donev; Maria Radanova; Mariana Eneva; Eleonora Dimitrova; Georgi Valchev; Velko Minchev; Margarita Taushanova; Teodora Karanikolova; Marsella Boneva; Radostina Gencheva; Anika Ivanova; Nikolay Conev; Bozhil Robev; Constanta Timcheva; Boian Pavlov; Vera Megdanova
• 出版年月日等: 2020-04-27
• 出版年（W3CDTF）: 2020-04-27
• 掲載年月日（W3CDTF）: 2020-04-27
• 出版事項（掲載誌）: Authorea, Inc.
• 対象利用者: 一般
• DOI: 10.22541/au.158802179.91839888; https://doi.org/10.22541/au.158802179.91839888
• オンライン閲覧公開範囲: インターネット公開
• 参照: Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report; https://cir.nii.ac.jp/crid/1871709542571479680
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/